title: [Hormone therapy effect in postmenopausal women with history of endometrial cancer].
abstract: BACKGROUND
  The increase of endometrial cancer survivors' incidence let the question if the management of postmenopausal hormone therapy will increase the risk of carcinogenesis.
  
  
  OBJECTIVE
  To determine the recurrence rate, in postmenopausal patients managed with hormonal therapy (HT) compared with patients without HT treated in El Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes.
  
  
  METHODS
  Retrospective, analytical, historical cohort. We analyzed 29 patients who met the inclusion criteria from January 1, 2000 to December 31, 2008 RESULTS: The average age for diagnosis of endometrial cancer was 45 years. 100% of the patients had surgical treatment (82.8% routine endometrial open approach, laparoscopic 17.2%). The 93% of patients had criteria to begin HT, however, was administered alone to 37% due to medical criteria, 36% received tibolona, 64% received estrogen with an average administration time of 39 and 54 months for each one without affecting disease-free period. Patients who received hormonal therapy had no recurrence of disease-free period of 58 months. There was only one patient with recurrence for which no hormonal therapy was administered.
  
  
  CONCLUSIONS
  Patients who were under hormonal therapy did not modify the rate of endometrial cancer recurrence compared with those without HT. Although we cannot conclude irrefutably the safety of hormone therapy, based on biological knowledge and the results of this study, hormone therapy can be safely administered in stage I and II.
authors.affiliation: Jefe del departamento de Ginecología y Obstetricia, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Secretaría de Salud, México, DF. acaarteaga@yahoo.com.mx
authors.forename: Ana Cristina
authors.initials: AC
authors.lastname: Arteaga-Gómez
authors.forename: Guillermo
authors.initials: G
authors.lastname: Castellanos-Barroso
authors.forename: Alinne
authors.initials: A
authors.lastname: Colin-Valenzuela
authors.forename: Jorge
authors.initials: J
authors.lastname: García-Vargas
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Márquez-Acosta
authors.forename: Enrique
authors.initials: E
authors.lastname: Reyes-Muñoz
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000601:surgery; D000328:Adult; D018196:Carcinoma, Adenosquamous / Q000453:epidemiology / Q000601:surgery; D018269:Carcinoma, Endometrioid / Q000453:epidemiology / Q000601:surgery; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D016889:Endometrial Neoplasms / Q000453:epidemiology* / Q000601:surgery; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008875:Middle Aged; D009367:Neoplasm Staging; D009652:Norpregnenes / Q000009:adverse effects / Q000627:therapeutic use; D017698:Postmenopause; D012008:Recurrence; D012189:Retrospective Studies; D012907:Smoking / Q000453:epidemiology
chemical_list: D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; C027385:tibolone